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Since the critical care physician will most likely be
involved in a life-threatening expression of systemic
mastocytosis, recognition of this disease is of utmost
importance in the critical care management of these
patients. Mastocytosis is a severely under-recognized
disease because it typically occurs secondary to another
condition and thus may occur more frequently than
assumed. In this article, we will review the current
knowledge on the treatment of mastocytosis crises
with an emphasis on critical care management.
Mastocytosis is characterized by the clonal proliferation
and accumulation of mast cells in different tissues. Mast
cell mediators contain a wide range of biologically
active substances that may lead to itching and hives
but may ultimately lead to anaphylactic shock caused
by the release of histamine and other mediators from
mast cells. The mainstay of therapy is the avoidance of
potential triggers of mast cell degranulation and, if
unsuccessful, blocking the cascade of mast cell mediators.
The critical care physician should be well aware of
the special precautions which should be kept in
mind throughout the management of a mastocytosis
crisis to avoid massive mast cell degranulation.
Histamine-releasing drugs and certain physical triggers
like temperature change should be avoided.be between 1:1,000 and 2:100,000, but several casesIntroduction
Mastocytosis is characterized by the clonal proliferation
and accumulation of mast cells in different tissues, with a
preferential localization in the skin and bone marrow. The
clinical presentation of mastocytosis is heterogeneous,
ranging from skin-limited to a more aggressive systemic
variant [1]. Mast cells produce and release a large
number of different mediators, which are either released* Correspondence: w.m.van.den.bergh@umcg.nl
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article, unless otherwise stated.continuously or stored in granules and released after
stimulation (Table 1). Signs and symptoms are caused by
release of these mast cell mediators or local accumulation
of mast cells [2, 3]. The disease may be undiagnosed until
patients are exposed to elicitors of mast cell degranulation
leading to severe anaphylactic reactions and even death
[4–7]. Anaphylaxis may be the result of a variety of
triggers. Several case reports described anaphylaxis
following regional or general anaesthesia as the first
presentation of mastocytosis [8, 9]. The diagnosis may
be difficult as anaphylaxis may develop with a delay of
hours [10]. Furthermore, drugs that are known potential
mast cell elicitors are frequently used pharmaceuticals
in the ICU [9]. Physicians should therefore realise that
adjustment of management to avoid trigger application is
necessary in order to prevent further endangerment of
vital functions. However, owing to the low but probably
under-reported prevalence of the disease, most critical
care physicians are not familiar with the management of
the patient with mastocytosis. In the following sections,
we review the pathogenesis and prophylactic measures of
mast cell mediator release, with an emphasis on critical
care management.Mastocytosis
Incidence and prevalence
The incidence of mastocytosis has been estimated to
are not recognized as caused by mastocytosis [2, 11].
The prevalence of mastocytosis was recently studied
in the adult population of the Groningen region in The
Netherlands and appeared to be at least 13 cases per
100,000 inhabitants [12].Pathophysiology
Mast cells develop from pluripotent stem cells in the
bone marrow and spleen. In mastocytosis, the majority of
cases are associated with gain-of-function point mutations
of KIT, a tyrosine kinase receptor located on mast cells.
As a consequence, the receptor is continuously activated,Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Effects of mast cell mediators in mastocytosis
Mediator(s) Features
Cardiovascular
Prostaglandins Flushing (increased heart rate and increased cardiac output)
Protease (Chymase) Increased blood pressure
Histamine Increased vasopermeability
Histamine, prostaglandin D2, leukotrienes, and platelet-activating factor Vasodilatation and hypotension
Platelet-activating factor Arrhythmia
Cutaneous
Histamine, prostaglandin D2, and platelet-activating factor Urticaria with or without angioedema
Histamine Pruritus
Respiratory
Histamine, leukotrienes, prostaglandin D2, and platelet-activating factor Bronchusconstriction
Prostaglandin D2 and leukotrienes Increased mucus production
Platelet-activating factor and leukotrienes Pulmonary oedema
Histamine Rhinitis
Gastrointestinal
Histamine Increased gastric acid secretion
Histamine Diarrhoea
Platelet-activating factor Abdominal ache
Hematologic
Heparin and proteases Coagulation disturbances
Remainder
Histamine Headache
Heparin, interleukin-6 (IL-6), and tryptase Osteopenia and osteoporosis
Pro-inflammatory cytokines (for example, tumour necrosis factor-alpha) and
chemokines
Fatigue, weight loss, local inflammation, oedema
formation, and leukocyte migration
Growth factor (IL-6) Fever
Tryptase Endothelial activation with consecutive inflammatory
reactions
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cells (Fig. 1) [2]. Mast cell progenitors are the only
myeloid cells that exit the bone marrow before complete
maturation. The destination of mast cells is beneath or in
the epithelium, close to vessels, smooth muscle cells, and
glandular tissue, where they act as outposts of the immune
system against exogenous allergens and pathogens [2].
Subjects with mastocytosis can experience non-specific
symptoms like generalized pruritus, flushing, diarrhoea,
abdominal pain, anaphylaxis, and osteoporosis due to a
release of mast cell mediators, weight loss, malabsorbtion,
cytopenia, organomegaly, and bone pain and fracture
due to infiltration of mast cells in organs in advanced
or aggressive mastocytosis [1].
Diagnosis and classification
Mastocytosis is classified by the World Health Organization
(WHO) in the category of ‘myeloproliferative neoplasms’and can be subdivided into cutaneous and systemic masto-
cytosis and mast cell neoplasm (Table 2). To establish
the diagnosis of systemic mastocytosis, either one
major and two minor or three minor WHO criteria
have to be fulfilled (Table 3). The indolent form is
the most prevalent subtype of systemic mastocytosis
[13]. An increased basal level of the mast cell mediator
tryptase (more than 20 ng/mL) in serum may indicate
the presence of the disease [14]. When mastocytosis
is suspected (for example, in a patient presenting with
anaphylactic shock due to a wasp sting), a marked
increased tryptase concentration is the hallmark of the
diagnosis [1]. One can also expect to find coagula-
tion disturbances, caused by the mast cell mediators
heparin and protease, and (methyl)histamine in urine.
In this particular example, immunoglobulin (Ig) against
wasp-antigen (rVes v5) shall be positive, revealing an
IgE-mediated reaction [1, 13, 14].
Fig. 1 Simplified pathophysiology of mastocytosis. The vast majority of patients with mastocytosis have a gain-of-function mutation in the
KIT-receptor gene. KIT encodes for a tyrosine kinase which functions as a receptor (CD117) for the stem cell factor (formally known as mast
cell growth factor). The mutation results in continuous activation and stimulation even without binding with the mast cell growth factor
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Stimulation of mediator release occurs by either IgE- or
non-IgE-mediated mechanisms, including physical stimuli
and drugs. The marked increased mediator release from
the elevated mast cell numbers explains the much higher
incidence as well as severity of anaphylaxis in mastocytosis
patients as compared with the general population [3].
Symptoms appear to be more severe in patients with
extensive systemic disease, which is reflected by a higher
serum tryptase level [15]. A study that described the
trigger factors for anaphylaxis in patients with masto-
cytosis found that the major precipitating agents were
Hymenoptera (wasps, bees, ants, and flies) stings (27 %),
foods (24 %), and medications (18 %) [15]. The prevalence
of Hymenoptera venom allergy among patients with
mastocytosis varies between 23 % and 47 % [11, 12].
Hymenoptera stings mostly cause severe anaphylactic
reactions (grade III), whereas foods and medication leadto milder systemic reactions (grade II). However, fatal
cases of drug hypersensitivity have been described in the
literature [7, 8]. Medications that are potential initiators of
mastocyte degranulation on the basis of case reports
and drugs associated with histamine release in general
are listed in Table 4.
Critical care management
Anaphylactic shock and complications are related to
mast cell degranulation; that is, spontaneous bleeding
may present features of mastocytosis [6, 16]. When
present, shock needs to be treated with the usual
treatment, including the administration of epinephrine.
For all patients with mastocytosis, epinephrine should
be readily available as it hinders mast cell degranulation
and is the first drug of choice during haemodynamic
failure in these patients [7]. Haemorrhage with dis-
turbed coagulation tests can be treated with protamin




- Diffuse cutaneous mastocytosis
- Mastocytoma of skin
2. Systemic mastocytosis
Indolent systemic mastocytosis - Smouldering systemic mastocytosis Isolated bone marrow mastocytosis
Aggressive systemic mastocytosis - Lymphadenopathic systemic mastocytosis with eosinophilia
Systemic mastocytosis with an associated non-mast
cell lineage disorder
- Systemic mastocytosis with myelodysplastic syndrome
- Systemic mastocytosis with myeloproliferative disorder
- Systemic mastocytosis with chronic myelomonocytic leukaemia
- Systemic mastocytosis with non-Hodgkin’s lymphoma
- Systemic mastocytosis with hypereosinophilic syndrome
Mast cell leukaemia - Aleukaemic mast cell leukaemia
3. Mast cell neoplasms
Mast cell sarcoma
Extracutaneous mastocytoma
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coagulant effects of heparin [9].
It is important to realise that, during further ICU
treatment, patients with mastocytosis are inevitably
exposed to triggers of mast cell degranulation, which
may be followed by severe anaphylactic responses [10].
When a patient with known mastocytosis is admitted to
the ICU, it may be helpful to make a risk profile to
estimate the chance of developing anaphylactoid reac-
tions. The risk profile includes the form of mastocytosis,
the basal serum tryptase level as a marker of the total
mast cell load, previous anaphylactic reactions, and
present mast cell activation status comprising recent
reactions to triggers. Histamine-releasing drugs, such as
opioids and neuromuscular blocking agents, should beTable 3 World Health Organization criteria for systemic
mastocytosis
Major criterion
- The existence of 15 or more multifocal mast cell clusters in the bone
marrow or in other tissue biopsies
Minor criteria
- Basal tryptase level of more than 20 ng/mL
- Either (a) more than 25% of mast cells in infiltrates of bone marrow or
other extracutaneous organs are atypical or spindle-shaped or (b) more
than 25% of mast cells in bone marrow aspirate are immature or atypical.
- Co-expression of CD117 with CD25 or CD2 (or both) on mast cells
- Codon 816 mutation in the C-KIT gene
To establish the diagnosis of systemic mastocytosis, either one major and two
minor or three minor World Health Organization criteria have to be fulfilled.
Patients who have a history of mast cell activation symptoms without skin
lesions but who do not fully meet diagnostic criteria for systemic mastocytosis
are classified as having mast cell activation syndrome [9, 17]avoided (Table 4). Additionally, infusion of cold solutions,
trauma, friction, and other mechanical factors are elicitors
of mast cell degranulation and should be prevented. Also,
several antibiotics and radio contrast materials are known
activators of mast cells [9]. Even anxiety may trigger mast
cell degranulation, for which benzodiazepines may be
considered. Continuous infusion of medication and
solutions theoretically leads to less release of mast cell
mediators and is preferred over single boluses.
When (surgical) intervention is planned during ICU
admission, precautions must be taken. The anaesthetist
should be conscious of the potential triggers and conse-
quences of mast cell degranulation and be informed about
the risk profile of the patient. Pre-medication may include
benzodiazepines, H1- and H2-receptor antagonists to block
the cascade of mast cell mediators, and glucocorticoids as
anti-inflammatory and mast cell stabilizers. Because mast
cell degranulation has been observed hours after trigger
application, we recommend continuing medication for at
least 4 hours after trigger application. Non-steroidal anti-
inflammatory drugs (NSAIDs) are effective prophylactic
drugs because of their antiprostaglandin actions. However,
they should be given only to patients who have received
these drugs previously, as NSAIDs are also associated with
serious anaphylactoid reactions [9].
Conclusions
Mastocytosis is a clonal disorder characterized by the
proliferation and accumulation of mast cells in different
tissues. After trigger application, an overwhelming release
of mast cell mediators may lead to severe haemodynamic
compromise and multi-organ failure. Knowledge of the
Table 4 Medications which are known potential triggers of mast cell degranulation




















van der Weide et al. Critical Care  (2015) 19:238 Page 5 of 5pathophysiology of the disease is of paramount importance
for adequate treatment and the prevention of secondary
events of mast cell degranulation due to mechanical or
pharmacological triggers. During treatment, physicians
should avoid potential triggers of mast cell degranulation,
consider giving pre-medication before interventions, and be
aware of and prepared for the clinical manifestations caused
by mast cell mediators. Avoiding medication and physical
stimuli that trigger histamine release and blocking the
cascade of actions of mast cells constitute the mainstay of
therapy besides treatment of anaphylaxis.
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